Literature DB >> 23909397

Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008.

Vivien Mak1, Dennis Ip, Oscar Mang, Chinmay Dalal, Steven Huang, Alina Gerrie, Tanya Gillan, Khaled M Ramadan, Cynthia Toze, Wing-Yan Au.   

Abstract

The incidence of chronic lymphocytic leukemia (CLL) in the Asian population is up to 10 times lower than that in Caucasians. Studies on CLL in Asian residents in North America may help to determine the relative genetic and environmental causes of such a difference. Computerized records of CLL incidence from the combined British Columbia (BC) databases (n = 2736) and the Hong Kong Cancer Registry (HKCR, n = 572) were traced. Ethnic Chinese cases of CLL in BC were identified (n = 35). The world age standardized rates (WASRs) of CLL (per 100 000) were calculated in BC (1.71), HK (0.28) and BC Chinese (0.4), respectively. Using standard incidence ratios (SIRs), the observed BC Chinese case number was comparable to the figure projected from HK rates (SIR 1.3, p = 0.1) but significantly lower than the figure following BC rates (SIR 0.22, p < 0.0001). The difference was maintained over both genders, in all age groups and through the years. Our data over three decades suggest that genetic factors outplay environmental factors to give lower CLL rates in Chinese.

Entities:  

Mesh:

Year:  2013        PMID: 23909397     DOI: 10.3109/10428194.2013.827785

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Ethnic and geographic diversity of chronic lymphocytic leukaemia.

Authors:  Shenmiao Yang; Abraham M Varghese; Nitin Sood; Carlos Chiattone; Norah O Akinola; Xiaojun Huang; Robert Peter Gale
Journal:  Leukemia       Date:  2020-10-19       Impact factor: 11.528

2.  Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations.

Authors:  Loren Gragert; Stephanie Fingerson; Mark Albrecht; Martin Maiers; Matt Kalaycio; Brian T Hill
Journal:  Blood       Date:  2014-09-17       Impact factor: 22.113

3.  Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.

Authors:  Heng Li; Shu-Hua Yi; Wen-Jie Xiong; Hui-Min Liu; Rui Lyu; Ting-Yu Wang; Wei Liu; Shi-Zhen Zhong; Zhen Yu; De-Hui Zou; Yan Xu; Gang An; Zeng-Jun Li; Lu-Gui Qiu
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

4.  Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.

Authors:  John Zhai; Yan Qin; Jun Zhu; Yuqin Song; Zhixiang Shen; Xin Du; Candice Jamois; Michael Brewster; Yuankai Shi; Jun Shi
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

5.  Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.

Authors:  Thomas Sau-Yan Chan; Yuh-Shan Lee; Ilaria Del Giudice; Marilisa Marinelli; Caterina Ilari; Luciana Cafforio; Anna Guarini; Daryl Tan; Colin Phipps; Yeow-Tee Goh; William Hwang; Allan Zhi-Kai Goh; Lisa Lai-Ping Siu; Saliangi Wu; Chun-Yin Ha; Shek-Ying Lin; Chi-Hang Kwok; Chi-Kuen Lau; Kit-Fai Wong; Robin Foà; Yok-Lam Kwong; Eric Tse
Journal:  Oncotarget       Date:  2017-04-11

6.  Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.

Authors:  Yan Qin; Yuqin Song; Zhixiang Shen; Xin Du; Wei Ji; Wanling Hsu; Jun Zhu; Yuankai Shi
Journal:  Cancer Commun (Lond)       Date:  2018-05-30

7.  Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.

Authors:  Xiaojun Huang; Lugui Qiu; Jie Jin; Daobin Zhou; Xiequn Chen; Ming Hou; Jianda Hu; Yu Hu; Xiaoyan Ke; Junmin Li; Yingmin Liang; Ting Liu; Yue Lv; Hanyun Ren; Aining Sun; Jianmin Wang; Chunting Zhao; Mariya Salman; Steven Sun; Angela Howes; Jingzhao Wang; Peng Wu; Jianyong Li
Journal:  Cancer Med       Date:  2018-03-13       Impact factor: 4.452

8.  Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea.

Authors:  Jun Ho Yi; Gyeong-Won Lee; Ji Hyun Lee; Kwai Han Yoo; Chul Won Jung; Dae Sik Kim; Jeong-Ok Lee; Hyeon Seok Eom; Ja Min Byun; Youngil Koh; Sung Soo Yoon; Jin Seok Kim; Jee Hyun Kong; Ho-Young Yhim; Deok-Hwan Yang; Dok Hyun Yoon; Do Hyoung Lim; Won-Sik Lee; Ho-Jin Shin
Journal:  Blood Res       Date:  2021-12-31

9.  Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia.

Authors:  Marilisa Marinelli; Caterina Ilari; Yi Xia; Ilaria Del Giudice; Luciana Cafforio; Irene Della Starza; Sara Raponi; Paola Mariglia; Silvia Bonina; Zhen Yu; Wenjuan Yang; Lugui Qiu; Thomas Chan; Alfonso Piciocchi; Yok-Lam Kwong; Eric Tse; Jianyong Li; Anna Guarini; Wei Xu; Robin Foà
Journal:  Oncotarget       Date:  2016-04-12

10.  Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.

Authors:  Wen Shuai; Pei Lin; Paolo Strati; Keyur P Patel; Mark J Routbort; Shimin Hu; Peng Wei; Joseph D Khoury; M James You; Sanam Loghavi; Zhenya Tang; Hong Fang; Beenu Thakral; L Jeffrey Medeiros; Wei Wang
Journal:  Blood Cancer J       Date:  2020-08-26       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.